We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Alliance to Identify Biomarkers of Choline Deficiency

By Biotechdaily staff writers
Posted on 15 Oct 2003
A research collaboration to identify biomarkers indicative of choline deficiency has been announced by Paradigm Genetics, Inc. More...
(Research Triangle Park, NC, USA; www.paradigmgenetics.com) and the University of North Carolina at Chapel Hill (UNC, USA).

Choline is an essential nutrient in the human diet but the body does not synthesize enough to meet its demands. Choline deficiency has been implicated in the onset of liver damage in humans. Under the agreement, UNC will provide Paradigm with serum and urine samples collected as part of its research to determine the required daily amount of choline. Paradigm researchers will then perform biochemical analyses on the biofluid sample and identify the pathways and mechanisms that may be involved.

"Choline deficiency is known to cause progressive liver damage and has been associated with increased risk of hepatic cancer in experimental models,” said Thomas J. Colatsky, Ph.D., vice president of healthcare research for Paradigm. "Current serum markers of liver injury lack the sensitivity and specificity to differentiate among patients with simple or more complex forms of liver disease, and often fail to signal its early onset.”

Paradigm uses a systems biology approach to understand gene function in the context of biologic pathways, and to develop assays and biomarkers for molecular diagnostic solutions tailored to the needs of its partners. The company's proprietary Gene to Cell to System approach has four major components: gene expression profiling, biochemical profiling, phenotypic profiling, and data integration and coherence.





Related Links:
Paradigm
UNC

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Pipette Calibration System
Artel PCS®
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Alzheimer’s pathology can start 15 to 20 years before symptoms, and validated tools that reach patients earlier help pave the way for earlier detection. (Image Credit: Adobe Stock)

Alzheimer’s Blood Test Becomes First FDA-Cleared Option for Adults as Young as 40

C2N Diagnostics’ PrecivityAD2 blood test was cleared by the U.S. Food and Drug Administration (FDA) on August 20, 2026, for adults as young as 40 who are experiencing signs of cognitive impairment, according... Read more

Pathology

view channel
Image: Adrenal gland tumor stained with hematoxylin and eosin (top) and CYP11B2 (bottom) (Photo courtesy of Christofer Juhlin)

Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism

Primary aldosteronism is a common but underdiagnosed cause of hypertension, in which excess aldosterone promotes salt retention and raises blood pressure. Identifying the dominant source of hormone overproduction... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.